Oxford Instruments Sells Nanoscience Late In Financial Time
Oxford Instruments plc sold NanoScience, a quantum-focused company. Oxford Instruments plc, a FTSE 250 company, provides high-tech products and services to industry and research. Along with a delay in its annual financial results and a steep reduction in its share price, this disposal is reorganising the group.
Nanoscience divestment
Oxford Instruments has signed a contractual deal to sell its NanoScience division to US-based Quantum Design International (QDI). The transaction is for £60 million, including up to £3 million in quantum scaling system revenue deferred consideration. Carlson family office bought QDI in October 2024. QDI, headquartered in the US, delivers scientific, academic, and industrial research products and services worldwide.
It was reported that NanoScience was a “profitable quantum technology business”. In FY25, it earned £1 million in adjusted operating profit and £59 million in revenue. After returning to profitability and growth, Oxford Instruments hopes to “crystallize this value for shareholders” with this transaction.
The sale is scheduled to finalise in the third quarter pending regulatory approvals. Non-recurring transaction costs are expected to be £2–3 million in FY2025–2026. Around £4 million in NanoScience division expenses will remain with the business following the sale, however mitigation actions are expected to begin in FY2026–2027.
Why: Focus on Core Markets and Shareholder Value
Oxford Instruments sells NanoScience to refocus strategically. In keeping with a strategy to focus and invest in the best areas of potential to grow the firm and create value for shareholders', CEO Richard Tyson said the transaction helps the company reach its medium-term profitability targets. This approach will allow the corporation to focus on its surviving companies, which have growth and margin characteristics that will benefit shareholders.
Oxford Instruments will prioritise its three key markets:
Material inspection
Electronics manufactured from semiconductors
Medical and biological sciences
Oxford Instruments' “calculated assessment” of its portfolio led to a strategy shift to these well-established core markets from the “capital-intensive quantum sector”. The corporation prioritises operational efficiency, commercial execution, and cost management to boost profitability in these remaining divisions. Recent performance gains may be due to the spinoff from NanoScience, which focused resources and met medium-term margin expectations.
An upcoming share repurchase scheme will return up to £50 million to shareholders using sale earnings. This choice shows a priority for shareholder returns over quantum research and development. This strategy may attract investors in the near term, but it “may constrain the company’s ability to capitalise on future opportunities within the quantum technology space.”
Concurrent Announcements and Market Reaction
The NanoScience sale announcement coincided with two other major events:
Oxford Instruments delayed the presentation of its annual financial results, which were scheduled for the same day as the sale announcement. The company said BDO, its auditors, requested more time. The delay “introduces a degree of uncertainty, prompting questions about the underlying financial data and the divestment timing”. Oxford Instruments had previously projected a 13% increase in adjusted operating profit and 9% increase in revenue for the second half of its fiscal year. These data are preliminary and may change after audit verification.
Share Price Decline: Oxford Instruments shares fell almost 3% after these disclosures. Since the company has declined more than 25% annually, this contributes to a bigger trend. Investors' reaction “suggests scrutiny of the strategic shift and a reassessment of the company's future direction”.
Broader UK quantum sector implications
Oxford Instruments had sold its NanoScience section before. Following this, US-based IonQ acquired Oxford Ionics for $1.1 billion the same week. This “pattern of British quantum technology companies being acquired by US entities” casts doubt on the UK quantum sector's long-term competitiveness and innovation.
Observers worry about intellectual property erosion and local innovation in this key new area. If critical technology is transferred to larger US corporations, it “may diminish the UK's capacity for independent development” and reduce its share of future quantum technology economic benefits. Due to consolidation, the competitive environment may shift, giving larger, US-based corporations a dominant position in the growing quantum industry.